| abstract |
The present invention relates to the creation of a new mesylate salt of N- (5- (4- (4 - ((dimethylamino) methyl) -3-phenyl-1H-pyrazol-1-yl) pyrimidin-2-ylamino) -4-methoxy-2- morpholinophenyl) acrylamide, its new crystalline form and method of their preparation. More specifically, the present invention relates to the mesylate salt of N- (5- (4- (4 - ((dimethylamino) methyl) -3-phenyl-1H-pyrazol-1-yl) pyrimidin-2-ylamino) -4-methoxy-2 -morpholinophenyl) acrylamide, which is characterized by excellent stability, solubility and bioavailability when used not only alone but also in combination with other drugs, and has a high degree of purity, as well as its crystalline form and method of preparation. |